Abstract Number: 1286 • ACR Convergence 2022
Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center
Background/Purpose: Biological drugs have revolutionized the treatment of rheumatic diseases. However, increasing the use of biologics over the past few years has directly contributed towards…Abstract Number: 1312 • ACR Convergence 2022
Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture
Background/Purpose: Previous cost-effectiveness analyses in postmenopausal women (PmW) with osteoporosis (OP) demonstrated that sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) resulted in lower…Abstract Number: 1424 • ACR Convergence 2022
Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…Abstract Number: 1488 • ACR Convergence 2022
Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study
Background/Purpose: Patients with psoriatic arthritis (PsA) may be at increased risk of herpes zoster (HZ). HZ can involve a painful dermatomal rash and lead to…Abstract Number: 2006 • ACR Convergence 2022
Healthcare Resource Utilization and Economic Burden of Patients with Adequate and Inadequate Responses to Advanced Therapies for Rheumatoid Arthritis in Japan
Background/Purpose: Substantial numbers of patients with RA receiving advanced therapies including biologics, biosimilars, and Janus kinase inhibitors do not achieve ACR50 responses and lack of…Abstract Number: 2086 • ACR Convergence 2022
Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus
Background/Purpose: Remission and low disease activity (LDA) are associated with decreased flares, damage, and mortality. However, little is known about the impact of disease activity…Abstract Number: 0059 • ACR Convergence 2022
Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE), which develops in about one-third of SLE patients within…Abstract Number: 0067 • ACR Convergence 2022
Cost Per Responder in RA Patients Failing First Line Treatment
Background/Purpose: The Colombian healthcare system is under economic pressure like many other systems in the world. In that sense, treatment choice involves cost in addition…Abstract Number: 0283 • ACR Convergence 2022
The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)
Background/Purpose: Rheumatoid arthritis (RA) can be better controlled with the advent of biological disease modified anti rheumatic drug (bDMARDs) and JAK inhibitor (JAKi). However, these…Abstract Number: 0143 • ACR Convergence 2021
Economic and Healthcare Resource Use Burden of Systemic Sclerosis
Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…Abstract Number: 0239 • ACR Convergence 2021
Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). Fatigue has been shown to…Abstract Number: 0240 • ACR Convergence 2021
Economic Burden of Fatigue Among Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). The objectives of this study…Abstract Number: 0357 • ACR Convergence 2021
Identifying Predictors of Unemployment in Axial Spondyloarthropathy: Data from the Ankylosing Spondylitis Registry of Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis of the axial skeleton. Persistent disease activity can result in significant disability and affect ability to maintain…Abstract Number: 0424 • ACR Convergence 2021
Incremental Healthcare Costs of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Compared to Asthma: Retrospective Analysis of Commercial Claims Data in the United States (US)
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss Syndrome, is a rare, complex multisystem disorder, characterized by vascular inflammation and multisystem organ damage. EGPA manifests…Abstract Number: 0562 • ACR Convergence 2021
Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018
Background/Purpose: Little is known about inpatient epidemiology, economic burden and resource utilization of patients with ankylosing spondylitis (AS). The current study aims to describe those…
- 1
- 2
- 3
- …
- 7
- Next Page »